Lupin Ltd Share Price – NSE  / BSE

Pharmaceuticals, Mid Cap

The product is bioequivalent to Xigduo XR and will be marketed for the same indications as per the approved labeling.

Dapagliflozin and Metformin Hydrochloride is a combination medication used to improve glycemic control in adults with type 2 diabetes

Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.

The pharmaceutical company reported a 37.46% surge in consolidated net profit to Rs 1,175.55 crore in Q3 FY26 as against Rs 855.16 crore posted in Q3 FY25. Total revenue from operations jumped 24.26% year-on-year to Rs 7,167.52 crore in the quarter ended 31 December 2025.

The counter shed 0.10% to end at Rs 2,309.45 on the BSE.

The inspection was conducted from 13 April 2026 to 17 April 2026 and closed with the issuance of a Form-483 with three observations.

We will address the observations and respond to the U.S. FDA within the stipulated timeframe. We are committed to be compliant with CGMP standards across all our facilities,? Lupin stated.

Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.

The pharmaceutical company reported a 37.46% surge in consolidated net profit to Rs 1,175.55 crore in Q3 FY26 as against Rs 855.16 crore posted in Q3 FY25. Total revenue from operations jumped 24.26% year-on-year to Rs 7,167.52 crore in the quarter ended 31 December 2025.

The scrip had shed 0.10% to end at Rs 2324.25 on the BSE on Friday.

Lupin has incorporated a wholly owned subsidiary in Thailand in the name and style 'Lupin Thailand' on 17 April 2026.

The case forms part of the broader In re Generic Pharmaceuticals Antitrust Litigation, a multi-defendant proceeding involving several pharmaceutical companies accused of price-fixing and market allocation practices in generic drugs. The litigation is pending in Philadelphia, Pennsylvania.

The agreement states that Lupin Pharmaceuticals Inc. denies all allegations, and the settlement does not constitute any admission of liability or unlawful conduct. The settlement is an attempt by the company to resolve legacy legal exposures to avoid prolonged litigation costs and related uncertainties.

Under the agreement, Lupin Pharmaceuticals Inc. will pay $30 million for a full and final release of all claims by Humana against the company and its affiliates.

The settlement amount has already been provided for in the company?s prior consolidated financial statements,? Lupin said.

Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.

The pharmaceutical company reported a 37.46% surge in consolidated net profit to Rs 1,175.55 crore in Q3 FY26 as against Rs 855.16 crore posted in Q3 FY25. Total revenue from operations jumped 24.26% year-on-year to Rs 7,167.52 crore in the quarter ended 31 December 2025.

The scrip shed 0.28% to currently trade at Rs 2320 on the BSE.